StockData
BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30
$76.80−0.56 (-0.72%)

Close on Nov 17, 2026Market cap $14.96BP/E –Yield –

BridgeBio Pharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BridgeBio Pharma's operating income for the twelve months ending Sep 30, 2026 was -$364.24M. For fiscal 2025 it was -$523.41M. The highest annual figure on record is -$43.86M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$523.41M–
FY2024Dec 31, 2024-$592.97M–
FY2023Dec 31, 2023-$607.37M–
FY2022Dec 31, 2022-$512.20M–
FY2021Dec 31, 2021-$576.63M–
FY2020Dec 31, 2020-$474.48M–
FY2019Dec 31, 2019-$266.24M–
FY2018Dec 31, 2018-$183.66M–
FY2017Dec 31, 2017-$43.86M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$11.64M–
Q2 FY2026Jun 30, 2026-$107.08M–
Q1 FY2026Mar 31, 2026-$105.96M–
Q4 FY2025Dec 31, 2025-$139.56M–
Q3 FY2025Sep 30, 2025-$145.20M–
Q2 FY2025Jun 30, 2025-$134.28M–
Q1 FY2025Mar 31, 2025-$104.37M-30529.2%
Q4 FY2024Dec 31, 2024-$226.03M–
Q3 FY2024Sep 30, 2024-$191.75M–
Q2 FY2024Jun 30, 2024-$175.54M–
Q1 FY2024Mar 31, 2024$343.00K–
Q4 FY2023Dec 31, 2023-$177.42M–
Q3 FY2023Sep 30, 2023-$157.69M–
Q2 FY2023Jun 30, 2023-$146.10M–
Q1 FY2023Mar 31, 2023-$126.16M–
Q4 FY2022Dec 31, 2022-$129.23M–
Q3 FY2022Sep 30, 2022-$129.12M–
Q2 FY2022Jun 30, 2022-$80.18M–
Q1 FY2022Mar 31, 2022-$173.68M–
Q4 FY2021Dec 31, 2021-$165.61M–
Q3 FY2021Sep 30, 2021-$149.50M–
Q2 FY2021Jun 30, 2021-$94.02M–
Q1 FY2021Mar 31, 2021-$167.50M–
Q4 FY2020Dec 31, 2020-$127.49M–
Q3 FY2020Sep 30, 2020-$119.94M–
Q2 FY2020Jun 30, 2020-$124.57M–
Q1 FY2020Mar 31, 2020-$102.49M–
Q4 FY2019Dec 31, 2019-$78.64M–
Q3 FY2019Sep 30, 2019-$54.53M–
Q2 FY2019Jun 30, 2019-$69.32M–
Q1 FY2019Mar 31, 2019-$63.75M–
Q4 FY2018Dec 31, 2018-$65.58M–
Q3 FY2018Sep 30, 2018-$41.46M–

More BridgeBio Pharma figures

See a number that looks wrong?